Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Share Acquisitions

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through American Depositary Shares (ADS) on April 30, 2025, and May 1, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, reported changes in beneficial ownership.
• On April 30, 2025, Griffiths acquired 34,309 American Depositary Shares (ADS) at $3.66 each.
• On May 1, 2025, Griffiths acquired 75,266 ADS at $3.97 each.
• Each ADS is immediately convertible into three ordinary shares.
• Following these transactions, Griffiths directly owns 10,720,853 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a report of share acquisitions by a director, which could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about a company's prospects. Significant insider purchases can be seen as a positive sign.

Stakeholder Impact

• Shareholders may view the director's share purchases as a positive sign of confidence in the company's future.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, ADS, American Depositary Shares, Beneficial Ownership, Form 4, Director, Share Acquisition